The eight recommended digital technologies are: Asthmahub, Asthmahub for parents, AsthmaTuner, Digital Health Passport, Luscii, myAsthma, RDMP (Respiratory Disease Management Platform) and Smart ...
More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.
NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...
Lifileucel for previously treated unresectable or metastatic melanoma ID3863 Draft guidance Technology appraisal guidance 22 January 2026 Filgotinib for treating axial spondyloarthritis ID6594 ...
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
We’re delighted that NICE has approved bevacizumab for first- and second-line treatment in combination with chemotherapy for advanced bowel cancer patients in England and Wales, following a similar ...
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma TA1113 3 December 2025 3 December 2025 Talquetamab for treating relapsed and refractory ...
Suggested remit: To appraise the clinical and cost effectiveness of givinostat within its marketing authorisation for treating Duchenne muscular dystrophy in people 6 years and over. Anticipate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback